Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c01092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Pragya Kumari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Sciences and Centre for Advance Functional Materials, Indian Institute of Science Education and Research Kolkata, Mohanpur-741…. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Antineoplastic Agents, Head and Neck Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Wellcome Trust, National Institute of Biomedical Genomics, Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
The aggressiveness and recurrence of cancer is linked to cancer stem cells (CSCs), but drugs targeting CSCs may not succeed in the clinic due to the lack of a distinct CSC subpopulation. Clinical Pt(II) drugs can increase stemness. We screened 15 RuII or IrIII complexes with mesalazine or 3-aminobenzoate Schiff bases of the general formulas [Ru(p-cym)L]+, [Ru(p-cym)L], and [Ir(Cp*)L]+ (L = L1-L9) and found three complexes (2, 12, and 13) that are active against oral squamous cell carcinoma (OSCC) CSCs. There is a putative oncogenic role of transcription factors (viz. NOTCH1, SOX2, c-MYC) to enhance the stemness. Our work shows that imidazolyl-mesalazine ester-based RuII complexes inhibit growth of CSC-enriched OSCC 3D spheroids at low micromolar doses (2 μM). Complexes 2, 12, and 13 reduce stemness gene expression and induce differentiation markers (Involucrin, CK10) in OSCC 3D cultures. The imidazolyl-mesalazine ester-based RuII complex 13 shows the strongest effect. Downregulating c-MYC suggests that RuII complexes may target c-MYC-driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Sciences and Centre for Advance Functional Materials, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, Nadia, West Bengal, India.
- National Institute of Biomedical Genomics, Kalyani-741251, West Bengal, India.
ORCID-Profile: Souryadip Roy, Shilpendu Ghosh, Arindam Mukherjee
Förderung
- Wellcome Trust
- National Institute of Biomedical Genomics
- Council of Scientific and Industrial Research, India
- The Wellcome Trust DBT India Alliance
- Science and Engineering Research Board
- Department of Science and Technology, Ministry of Science and Technology, India
- University Grants Committee
- Indian Institute of Science Education and Research Kolkata
Zitieren
APA
Kumari, P., Ghosh, S., Acharya, S., Mitra, P., Roy, S., Ghosh, S., Maji, M., Singh, S., & Mukherjee, A. (2023). Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01092
Vancouver
Kumari P, Ghosh S, Acharya S, Mitra P, Roy S, Ghosh S, et al. Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01092
BibTeX
@article{Kumari2023,
author = {Kumari, Pragya and Ghosh, Subhashis and Acharya, Sourav and Mitra, Paromita and Roy, Souryadip and Ghosh, Shilpendu and Maji, Moumita and Singh, Sandeep and Mukherjee, Arindam},
title = {Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c01092}
}
EUVIMED